Tirzepatide: The Approved Dual Agonist
Tirzepatide occupies a position nothing else on this site does: it produced the largest weight reductions of any drug a doctor can actually prescribe today. Everything with bigger numbers is either investigational or unapproved. That combination — strong results plus an actual pharmacy pathway — makes it the practical benchmark against which compounds like retatrutide should be measured.
How it works
Tirzepatide activates two incretin receptors, GIP and GLP-1. GLP-1 activity slows gastric emptying and increases satiety; adding GIP appears to improve both the metabolic effect and, notably, the tolerability compared with GLP-1 activation alone. It is a once-weekly subcutaneous injection with a half-life supporting that schedule.
What the trials found
SURMOUNT-1 is the pivotal obesity trial: 2,539 adults, 72 weeks, published in theNew England Journal of Medicine. The headline result at the highest dose was a mean 20.9% body-weight reduction counting every randomized participant — the analysis convention this site uses throughout, so the figure is directly comparable to the other numbers in our GLP-1 comparison table.
Beyond weight, tirzepatide carries an approval for moderate-to-severe obstructive sleep apnea in adults with obesity — an outcome indication rather than a surrogate one — and is separately approved as Mounjaro for type 2 diabetes.
Approved indications and dosing
| Brand | Indication | Dose range |
|---|---|---|
| Zepbound | Chronic weight management in obesity, or overweight with a weight-related comorbidity; moderate-to-severe obstructive sleep apnea in adults with obesity | 2.5 mg starting, escalating in 2.5 mg steps; maximum 15 mg weekly |
| Mounjaro | Type 2 diabetes | Per label |
The label starts at 2.5 mg once weekly for four weeks — a dose intended for tolerability rather than efficacy — before stepping up. Escalation pace is the main lever a clinician has over gastrointestinal side effects.
Side effects
The profile is dominated by gastrointestinal effects — nausea, diarrhea, vomiting, constipation — concentrated during dose escalation and generally improving at a stable dose. The label carries the class boxed warning for thyroid C-cell tumors observed in rodents, with contraindications for personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, plus the standard pancreatitis, gallbladder and hypoglycemia-in-combination cautions.
Because tirzepatide has been in approved use for years, its safety picture rests on post-marketing data across a far larger and less selected population than any trial — an advantage no investigational compound can have. Oursafety overview puts this in context across compounds.
How it compares
| Compound | Targets | Best trial result, counting everyone | Status |
|---|---|---|---|
| Retatrutide | GIP + GLP-1 + glucagon | −25.0% at 80 weeks | Phase 3, not approved |
| Tirzepatide | GIP + GLP-1 | −20.9% at 72 weeks | Approved |
| Semaglutide | GLP-1 | −14.9% at 68 weeks | Approved |
Detailed head-to-head analysis is onretatrutide vs tirzepatide, and the full class table with both analysis conventions is in theGLP-1 comparison.
Prescription versus research-grade material
Tirzepatide is available by prescription, which makes the research-chemical version a different proposition from retatrutide's. With an approved product on the market, the only reasons to use unregulated material are cost and access — and the trade is a manufactured medicine with a reviewed process for a vial no regulator has evaluated. FDA has specifically warned about unapproved GLP-1 products sold for weight loss. If cost is the barrier, manufacturer savings programs bring real-world prices well below list; our cost comparison covers the numbers.
Research on Tirzepatide
7 records in our research database, classified by evidence type:
- HumanREDEFINE 4 head-to-head results versus tirzepatideNovo Nordisk · Company announcement, 2026
- HumanTirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)Aronne LJ et al. · New England Journal of Medicine, 2025
- HumanTirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)Jastreboff AM et al. · New England Journal of Medicine, 2022
- HumanTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)Frías JP et al. · New England Journal of Medicine, 2021
Tirzepatide — research vial — American Peptides
Research-use material, not the approved medicine. An approved prescription product exists for this molecule — that route comes with a label, a pharmacist and a reviewed manufacturing process, none of which apply here.
We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.
Frequently asked questions
What is tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, approved by the FDA as Zepbound for chronic weight management and obstructive sleep apnea, and as Mounjaro for type 2 diabetes. It is a once-weekly subcutaneous injection.
How much weight do people lose on tirzepatide?
In SURMOUNT-1, the pivotal 72-week obesity trial, the highest dose produced a mean 20.9% reduction counting every randomized participant. Individual results varied widely around that mean.
What is the tirzepatide dose?
The approved label starts at 2.5 mg once weekly for four weeks, then escalates in 2.5 mg increments. The maximum recommended dose is 15 mg once weekly. Dosing decisions belong with the prescribing physician.
Zepbound vs Mounjaro — what is the difference?
Same molecule, different approved indications and branding. Zepbound is approved for weight management and obstructive sleep apnea; Mounjaro is approved for type 2 diabetes. Which one a person is prescribed depends on the indication being treated.
Is research-grade tirzepatide the same as Zepbound?
No. Zepbound is a manufactured medicine with an FDA-reviewed manufacturing process, a label, and a supply chain. Research-grade material is unregulated, unevaluated by any regulator, and carries no assurance that the vial contains what it claims. The molecule may be nominally the same; the product is not.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022;387(3):205–216. PubMed
- ZEPBOUND (tirzepatide) prescribing information — indications, dose strengths, boxed warning. DailyMed label
- Drugs@FDA record for Zepbound. Drugs@FDA
- FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA
- Manufacturer self-pay pricing, checked 2026: Zepbound (Lilly).
Related guides
- Semaglutide: the most-studied GLP-1
- Retatrutide: the triple agonist in Phase 3
- Retatrutide vs tirzepatide, compared honestly
- Best peptides for weight loss, ranked
- Peptide reconstitution calculator